Lipid abnormalities associated with end-stage renal disease.
Patients undergoing chronic renal replacement therapy have a high incidence of dyslipidemia. In general, there are increased concentrations of triglyceride-rich apolipoprotein B-containing particles. These elevations lead to increased levels of non-high-density lipoprotein (HDL) levels. This pattern is further modified by the method of dialysis (peritoneal versus hemodialysis) and comorbidities such as diabetes. End-stage renal disease patients also demonstrate increased levels of lipoprotein(a) (Lp(a)) and oxidized low-density lipoprotein (LDL)both of which are highly atherogenic. This review focuses on the pathogenesis of these lipid abnormalities and their role in the atherosclerotic process.
Liu
Jia
J
Division of Nephrology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, Virginia 22908, USA.
Rosner
Mitchell H
MH
D050171:Dyslipidemias / Q000209:etiology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000378:metabolism* / Q000628:therapy; D050356:Lipid Metabolism; D006435:Renal Dialysis / Q000009:adverse effects